Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
- 1 June 2006
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 130 (7), 2039-2049
- https://doi.org/10.1053/j.gastro.2006.04.007
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA LevelJAMA, 2006
- Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 updateLiver International, 2005
- Viral hepatitis BThe Lancet, 2003
- Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis BClinical Infectious Diseases, 2003
- Hepatitis B viral resistance: mechanisms and diagnosisJournal of Hepatology, 2003
- Clinical Experience With LamivudineSeminars in Liver Disease, 2002
- Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapyHepatology, 2001
- Effects of extended lamivudine therapy in Asian patients with chronic hepatitis BGastroenterology, 2000
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997